Repository logo
  • AI Search Assistant Beta
    • English
    • 中文
    Log In
    Have you forgotten your password?
    1. Home
    2. College of Medicine / 醫學院
    3. School of Medicine / 醫學系
    4. Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
     
    • Details

    Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience

    Journal
    Dermatologica Sinica
    Journal Volume
    35
    Journal Issue
    1
    Pages
    25-29
    Date Issued
    2017
    Author(s)
    Wang, Ting-Shun
    CHIH-CHIEH CHAN  
    HSIEN-YI CHIU  
    TSEN-FANG TSAI  
    DOI
    10.1016/j.dsi.2016.09.005
    URI
    https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007382142&doi=10.1016%2fj.dsi.2016.09.005&partnerID=40&md5=11bbca5929371c01ca8a0e9f9ca88f67
    https://scholars.lib.ntu.edu.tw/handle/123456789/592063
    Abstract
    Background/Objective To date, no clinical trials have evaluated the therapeutic response among psoriasis patients switching from ustekinumab to secukinumab. The objective of this study was to report our experience of treating psoriasis patients with secukinumab therapy who had ever received ustekinumab previously. Methods We retrospectively reviewed the therapeutic responses of nine patients with moderate-to-severe psoriasis who attended the clinical trials of first ustekinumab and then secukinumab. Ustekinumab (45?mg) was given at Weeks 0, 4, and 16, and patients were evaluated for safety and efficacy at Weeks 12 and 16. After the end of the ustekinumab treatment period, patients were treated as needed by other modalities. In 2011, eligible patients were recruited again in a Phase 3, double-blind, secukinumab trial (ERASURE). Secukinumab (150?mg or 300?mg) was given at Weeks 0, 1, 2, 3, and 4 and then every 4 weeks. A single evaluator performed all the assessments. Results Among the nine patients, five patients (55.6%) had at least 75% reduction in the Psoriasis Area Severity Index (PASI75) score response, and four patients (44.4%) had at least 90% reduction in the Psoriasis Area Severity Index (PASI90) score response at Week 12 during secukinumab therapy. Their prior experience during ustekinumab therapy revealed at least PASI75 response in four patients (44.4%) and at least PASI90 response also in four patients (44.4%) at Week 12. Mean absolute PASI change at Week 12 of secukinumab therapy in our patients was??17.47. Conclusion Biologic switch is effective and valuable. Patients who have ever responded to ustekinumab seem to have a better response to secukinumab. ? 2016
    SDGs

    [SDGs]SDG3

    Other Subjects
    adalimumab; alefacept; cyclosporin; efalizumab; etanercept; etretin; methotrexate; psoralen; secukinumab; tofacitinib; ustekinumab; adult; Article; biological therapy; candidiasis; chickenpox; clinical article; comorbidity; disease duration; disease severity; double blind procedure; drug efficacy; drug safety; drug substitution; erythema annulare centrifugum; human; male; middle aged; monotherapy; open study; patient safety; periodontitis; phase 3 clinical trial; psoriasis; Psoriasis Area and Severity Index; recurrent disease; retrospective study; systemic therapy; topical treatment; treatment response; ultraviolet A radiation; ultraviolet B radiation; ultraviolet phototherapy; upper respiratory tract infection; urticaria
    Publisher
    Elsevier Ltd
    Type
    journal article

    臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

    To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

    總館學科館員 (Main Library)
    醫學圖書館學科館員 (Medical Library)
    社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

    開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

    • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
      Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
    • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
      Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
    • 網站簡介 (Quickstart Guide)
    • 使用手冊 (Instruction Manual)
    • 線上預約服務 (Booking Service)
    • 方案一:臺灣大學計算機中心帳號登入
      (With C&INC Email Account)
    • 方案二:ORCID帳號登入 (With ORCID)
    • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
    • 方案二:自行建檔 (Default mode Submission)
    • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

    Built with DSpace-CRIS software - Extension maintained and optimized by 4Science